What is the TRAVERSE trial and what did it prove about TRT safety?

The TRAVERSE trial (Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men) enrolled 5,246 men aged 45–80 with hypogonadism (total testosterone below 300 ng/dL) and pre-existing cardiovascular disease or high cardiovascular risk, randomized to TRT (testosterone cypionate) or placebo, and followed for a mean of 33 months, finding TRT non-inferior to placebo for the composite cardiovascular endpoint of death, heart attack, and stroke, but finding significantly higher rates of atrial fibrillation (16% higher) and pulmonary embolism (2.3× higher) in the TRT group (Lincoff et al., NEJM, 2023).

TRAVERSE was designed to definitively answer the TRT-cardiac safety question that had been debated since two small 2010 studies raised concerns. On the primary MACE endpoint, TRT cleared the non-inferiority hurdle, men with established cardiovascular disease or high risk did not have more heart attacks or strokes on TRT than on placebo. The safety signals that TRAVERSE clearly documented (AF, PE) are important clinical modifiers that should inform who gets TRT and how they are monitored.

Honesty Scale: Solid (1) for TRAVERSE's findings as the most definitive current evidence on TRT cardiovascular safety.

What to do: If a prescriber offers you TRT without mentioning TRAVERSE's atrial fibrillation and pulmonary embolism findings, ask specifically. These are not minor side effects, they are conditions that require their own cardiovascular risk assessment. A man with existing atrial fibrillation on anticoagulation and a man who has never had AF are in different risk categories for TRT.

For the full picture, read The Testosterone/TRT Deep Dive